Peptide-based combination nanoformulations for cancer therapy

Nanomedicine (Lond). 2020 Sep;15(22):2201-2217. doi: 10.2217/nnm-2020-0220. Epub 2020 Sep 11.

Abstract

Research in cancer therapy is moving towards the use of biomolecules in combination with conventional approaches for improved disease outcome. Among the biomolecules explored, peptides are strong contenders due to their small size, high specificity, low systemic toxicity and wide inter/intracellular targets. The use of nanoformulations for such combination approaches can lead to further improvement in efficacy by reducing off-target cytotoxicity, increasing circulation time, tumor penetration and accumulation. This review focuses on nanodelivery systems for peptide-based combinations with chemo, immuno, radiation and hormone therapy. It gives an overview of the latest therapeutic research being conducted using combination nanoformulations with anticancer peptides, cell penetrating/tumor targeting peptides, peptide nanocarriers, peptidomimetics, peptide-based hormones and peptide vaccines. The challenges hindering clinical translation are also discussed.

Keywords: cancer therapy; combination nanoparticles; drug-delivery systems; nanomedicine; peptide–drug nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell-Penetrating Peptides*
  • Drug Carriers / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Nanoparticles*
  • Neoplasms* / drug therapy

Substances

  • Cell-Penetrating Peptides
  • Drug Carriers